Israele - inglese - Ministry of Health

ferring pharmaceuticals ltd - mesalazine - enema - mesalazine 1 g / 100 ml - aminosalicylic acid and similar agents - ulcerative colitis - chron's disease

Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - vedolizumab, quantity: 331.2 mg - injection, powder for - excipient ingredients: polysorbate 80; arginine hydrochloride; histidine; sucrose; histidine hydrochloride monohydrate - ulcerative colitis,treatment of adult patients with moderate to severe ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnf-alpha) antagonist.,crohn?s disease,treatment of adult patients with moderate to severe crohn?s disease who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnf-alpha) antagonist.,pouchitis,entyvio is indicated for the treatment of adult patients with moderate to severe chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; propylene glycol; magnesium stearate; colloidal anhydrous silica; cellacefate; purified talc; macrogol 20000; povidone; carnauba wax; maize starch; glyceryl monostearate - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: pyralin en tablets are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Israele - inglese - Ministry of Health

takeda israel ltd - vedolizumab - powder for concentrate for solution for infusion - vedolizumab 300 mg/vial - vedolizumab - ulcerative colitis:entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (tnfα) antagonist.crohn’s disease:entyvio is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (tnfα) antagonist.

Israele - inglese - Ministry of Health

tradis gat ltd - mesalazine - tablets enteric coated - mesalazine 400 mg - mesalazine - " ulcerative colitis:-for the treatment of mild to moderate acute exacerbations. -for the maintenance of remission.crohn's disease:-for the treatment of acute episodes."

Israele - inglese - Ministry of Health

tradis gat ltd - mesalazine - tablets enteric coated - mesalazine 800 mg - mesalazine - " ulcerative colitis:-for the treatment of mild to moderate acute exacerbations. -for the maintenance of remission.crohn's disease:-for the treatment of acute episodes."

Israele - inglese - Ministry of Health

takeda israel ltd - vedolizumab - solution for injection - vedolizumab 158.8 mg / 1 ml - vedolizumab - ulcerative colitisentyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnfα) antagonist.crohn’s diseaseentyvio is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnfα) antagonist.

Israele - inglese - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - tablets prolonged release - upadacitinib as hemihydrate 45 mg - upadacitinib - ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - hydrocortisone acetate, quantity: 10 mg/g - eye ointment - excipient ingredients: white soft paraffin; liquid paraffin; wool fat - inflammatory conditions of the eye, including allergic conjunctivitis, nonpurulent conjunctivitis and/or blepharitis, iritis, herpes zoster ophthalmicus, recurrent marginal ulceration.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methylprednisolone acetate, quantity: 40 mg/ml - injection, suspension - excipient ingredients: hydrochloric acid; macrogol 3350; miripirium chloride; sodium chloride; sodium hydroxide - indications as at 17 november 2004: a.for intramuscular administration. when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of depo-nisolone is indicated as follows: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia. hypercalcaemia associated with cancer. non-suppurative thyroiditis. 2. rheumatic disorders. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis. epicondylitis. synovitis of osteoarthritis. acute non-specific tenosynovitis. rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). acute gouty arthritis. psoriatic arthritis. ankylosing spondylitis. acute and subacute bursitis. 3. collagen diseases. during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus. acute rheumatic carditis. systemic dermatomyositis (polymyositis). 4. dermatological diseases. pemphigus. bullous dermatitis herpetiformis. severe erythema multiforme (stevens-johnson syndrome). severe seborrhoeic dermatitis. exfoliative dermatitis. severe psoriasis. mycosis fungoides. 5. allergic states. control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: bronchial asthma. drug hypersensitivity reactions. contact dermatitis.urticarial transfusion reactions. atopic dermatitis. acute non-infectious laryngeal oedema (adrenaline is the drug of first choice). serum sickness. 6. ophthalmic diseases. severe acute and chronic allergic and inflammatory processes involving the eye, such as: herpes zoster ophthalmicus. sympathetic ophthalmia. iritis, iridocyclitis. anterior segment inflammation. chorioretinitis. allergic conjunctivitis. diffuse posterior uveitis. allergic corneal marginal ulcers. optic neuritis. keratitis. 7. gastrointestinal diseases. to tide the patient over a critical period of the disease in: ulcerative colitis (systemic therapy). regional enteritis (systemic therapy). 8. respiratory diseases.symptomatic sarcoidosis. berylliosis. fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy. aspiration pneumonitis. loeffler's syndrome not manageable by other means. 9. haematological disorders. acquired (autoimmune) haemolytic anaemia. erythroblastopenia (rbc anaemia). secondary thrombocytopenia in adults. congenital (erythroid) hypoplastic anaemia. 10. neoplastic diseases. for palliative management of: leukaemias and lymphomas in adults. acute leukaemia in childhood. 11. oedematous states. to induce diuresis or remission of proteinuria in the nephrotic syndrome without uraemia of the idiopathic type or that due to lupus erythematosus. 12. miscellaneous. tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy. trichinosis with neurological or myocardial involvement. b. for intra-articular or soft tissue administration depo-nisolone is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis. epicondylitis. rheumatoid arthritis. acute non-specific tenosynovitis. acute and subacute bursitis. post-traumatic osteoarthritis. acute gouty arthritis. c. for intralesional administration. depo-nisolone is indicated for intralesional use in the following conditions: keloids.discoid lupus erythematosus. necrobiosis lipoidica diabeticorum. alopecia areata. localised hypertrophic, infiltrated inflammatory lesions of licen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis). depo-nisolone may also be useful in cystic tumours of an aponeurosis or tendon (ganglia).